Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences Director Jeffrey Bluestone exercised stock options and sold 5,000 shares of common stock for $123.50 per share under a pre-arranged trading plan.

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock for $124.31 per share on January 15, 2026, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, filed a Form 4 disclosing a planned sale of 3,000 shares of common stock in January 2026 under a Rule 10b5-1 plan.

Gilead Sciences' Chief Medical Officer, Dietmar Berger, reported the vesting and subsequent sale of shares from restricted stock units.

Gilead Sciences Chairman and CEO Daniel O'Day sold 10,000 shares of common stock for approximately $1.25 million, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock for $122 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, reported the sale of 3,000 shares of common stock at $122 per share, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences CFO Andrew D. Dickinson reported the vesting of restricted stock units and subsequent sale of shares for tax obligations, a routine insider transaction.

Gilead Sciences Chairman & CEO Daniel P. O'Day exercised 10,426 restricted stock units and sold 4,931 shares of common stock to cover tax liabilities.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, reported the acquisition of common stock through RSU conversion and subsequent sale of shares for tax obligations.

Gilead Sciences Director Kelly A. Kramer exercised stock options and subsequently sold common stock under a Rule 10b5-1 trading plan.

Gilead Sciences Director Jeffrey Bluestone exercised 5,000 stock options and simultaneously sold the acquired shares for a profit on November 28, 2025.

Gilead Sciences CEO Daniel O'Day sold 10,000 shares of common stock on November 28, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences, a 10% owner and director of Xilio Therapeutics, converted 13.3 million Series B Warrants into Prefunded Warrants, increasing its beneficial ownership.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock for $125.23 per share, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, exercised stock options and subsequently sold a portion of her shares as part of a pre-arranged trading plan.

Gilead Sciences' EVP of Corporate Affairs and General Counsel, Deborah H. Telman, exercised stock options and subsequently sold common stock totaling 53,646 shares under a pre-arranged trading plan.

Gilead Sciences CEO Daniel O'Day sold 10,000 shares of common stock on October 28, 2025, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences EVP Deborah Telman reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Gilead Sciences CFO Andrew D. Dickinson sold 2,500 shares of common stock for $118.08 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Gilead Sciences Chief Commercial Officer Johanna Mercier sold 3,000 shares of common stock for $118.08 per share on October 15, 2025, under a pre-arranged trading plan.

Gilead Sciences, a 10% owner and director, acquired additional common stock and warrants in Assembly Biosciences through a private placement.

Gilead Sciences CEO Daniel O'Day sold a total of 10,000 shares of common stock on September 29, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences, Inc. SVP of Controllership, Erin Burkhart, was granted 8,890 restricted stock units with a four-year vesting schedule.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, sold 3,000 shares of common stock for $113.57 per share under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock for $113.57 per share under a pre-arranged trading plan.

Gilead Sciences CEO Daniel O'Day exercised restricted stock units and acquired common stock, with a portion sold to cover tax liabilities.

Gilead Sciences' Interim Corporate Controller and CAO, Diane E. Wilfong, reported the acquisition of common stock through RSU vesting and a subsequent sale for tax obligations.

Gilead Sciences' EVP Deborah H. Telman reported the vesting of restricted stock units and subsequent share sales for tax obligations.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, reported the acquisition of common stock through RSU vesting and a subsequent sale to cover tax liabilities.